Table 4.
Characteristics of T cell deficiency patients
| No BCGosis | BCGosis | p value | |
|---|---|---|---|
| Num of pts (%) | 15 (62.5) | 9 (37.5) | |
| Age at HSCT, months (STD) | 34.2 (37.6) | 9.9 (3.7) | 0.045 |
| Num of patients with SCID (%) | 3 (20) | 5 (55.6) | 0.099 |
| Num of patients with Omenn (%) | 3 (20) | 2 (22.2) | 1.0 |
| Pre-HSCT ALC 106/L (STD) | 4060 (4302) | 9569 (17000) | 0.676 |
| Pre HSCT Immunophenotyping cells/μl, mean (STD)a | |||
| CD3 | 2425 (2843) | 3614 (8480) | 0.083 |
| CD4 | 859 (1235) | 2719 (6116) | 0.296 |
| CD8 | 1226 (1512) | 951 (1504) | 0.296 |
| CD19 | 844 (903) | 690 (694) | 0.765 |
| NK | 698 (758) | 243 (427) | 0.03 |
| Num pts with pre-HSCT BCGosis (%) | 0 | 3 (33.3) | 0.042 |
| Pts on anti-mycobacterials primary prophylaxis (%)b | 4 (26.7) | 4 (66.7) | 0.15 |
| Day of neutrophil engraftment (STD, num of pts)c | 18.9 (6.9, 14) | 15.4 (6.0, 8) | 0.206 |
| Post-HSCT day of BCG complication (STD, num of pts) | 34.0 (15.8, 5) | 65.7 (145.4, 9) | 0.257 |
| Day 100 ALC, 106/L (STD, num of pts) | 4223(2730, 13) | 2275 (2935, 8) | 0.017 |
| Day 100 chimerism (STD, num of pts) | 87.4 (23.8, 12) | 53.4 (40.1, 8) | 0.091 |
| Number of pts with aGVHD grade > 2 (%) | 1 (6.7) | 3 (33.3) | 0.13 |
| Number of pts with cGVHD (%) | 2 (18.2) | 0 | 1 |
| Mean length of follow-up (STD) | 41.7 (30.2) | 22.6 (18.0) | 0.144 |
| Last follow-up ALC, 106/L (STD, num of pts) | 4006 (3417, 14) | 3040 (2147, 9) | 0.659 |
| Last follow-up chimerism (STD, num of pts) | 78.2 (28.8, 13) | 47.4 (43.8, 8) | 0.097 |
| Last immunophenotyping cells/μl, mean (STD)d | |||
| CD3 | 3114 (3208) | 2304 (932) | 1 |
| CD4 | 1117 (1202) | 1389 (866) | 0.329 |
| CD8 | 1720 (2034) | 872 (478) | 0.77 |
| CD19 | 496 (375) | 862 (990) | 0.558 |
| NK | 331 (360) | 297 (446) | 0.558 |
| Num of pts on IVIG at last follow-up (%) | 3 (23.1) | 1 (16.7) | 1 |
| Survival—number of pts (%) | 13 (86.7) | 6 (66.7) | 0.326 |
aGVHD acute graft vs host disease, BCG bacillus Calmette–Guerin, cGVHD chronic graft vs host disease, ALC absolute lymphocyte count, DLI donor lymphocyte infusion, IVIG intravenous immunoglobulins, num number, Pts patients, STD standard deviation
aPre-transplant lymphocyte immunophenotyping was recorded for 14 patients of the non-BCGosis group and 7 patients of the BCGosis group
bPercentage of patients receiving primary prophylaxis is calculated of the number of pre-transplant asymptomatic patients
cNeutophil engraftment–defined as the first day of 3 consecutive days of ANC > 500
dLast follow-up lymphocyte count was recorded for 10 patients of the non-BCGosis group and 7 patients of the BCGiosis group